<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03289052</url>
  </required_header>
  <id_info>
    <org_study_id>43CH1626</org_study_id>
    <nct_id>NCT03289052</nct_id>
  </id_info>
  <brief_title>Restylane Volyme for Correction of Midface Volume Deficit and/or Midface Contour Deficiency</brief_title>
  <official_title>A Randomized, Multi-center, Evaluator-blinded, No-treatment Controlled Study to Evaluate the Effectiveness and Safety of Restylane Volyme for Correction of Midface Volume Deficit and/or Midface Contour Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Q-Med AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Q-Med AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, evaluator-blinded, no-treatment controlled study in subjects with
      Midface Volume Deficit and/or Midface Contour Deficiency.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Actual">July 30, 2019</completion_date>
  <primary_completion_date type="Actual">January 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline using validated scale at 6 months</measure>
    <time_frame>6 month</time_frame>
    <description>Change from baseline using validated scale at 6 months</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">168</enrollment>
  <condition>Midface Volume Deficit</condition>
  <arm_group>
    <arm_group_label>Restylane Volyme</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single injection and optional touch up injection with Restylane Volyme in Midface</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No intervention arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Restylane Volyme</intervention_name>
    <description>Subcutis injection</description>
    <arm_group_label>Restylane Volyme</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent

          2. Men or women aged 18 years of age or older of Chinese origin

          3. Subjects willing to abstain from any other facial plastic surgical or cosmetic
             procedures below the level of the lower orbital rim for the duration of the study

          4. Subjects seeking augmentation therapy for the midface

          5. MMVS score of 2, 3 or 4 on each side of the face as assessed by the blinded evaluator

        Exclusion Criteria:

          1. Known/previous allergy or hypersensitivity to any injectable HA gel/local
             anaesthetics, e.g.lidocaine or other amide-type anaesthetics.

          2. Previous surgery or tattoo in the area to be treated

          3. Previous tissue augmentation therapy or contouring with any permanent
             (non-biodegradable) or semi-permanent filler, autologous fat, lifting threads or
             permanent implant below the level of the lower orbital rim.

          4. Previous use of any hyaluronic acid based or collagen based biodegradable facial
             tissue augmentation therapy below the level of the lower orbital rim or neurotoxin
             within 9 months before treatment.

          5. Scars or deformities, active skin disease, inflammation or related conditions, such as
             infection, perioral dermatitis, seborrheic eczema, rosacea, acne psoriasis and herpes
             zoster near or in the area to be treated.

          6. Other condition preventing the subject from entering the study in the Investigator's
             opinion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Q-Med AB</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>September 18, 2017</study_first_submitted>
  <study_first_submitted_qc>September 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2017</study_first_posted>
  <last_update_submitted>August 28, 2019</last_update_submitted>
  <last_update_submitted_qc>August 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyaluronic acid, midface</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

